1. Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives
   Pei Shi Ong et al, 2016, Front. Pharmacol. CrossRef
2. Immunological characteristics of Mycobacterium tuberculosis subunit vaccines immunized through different routes
   Yanzhi Lu et al, 2018, Microbial Pathogenesis CrossRef
3. Preclinical Evidence for Targeting PI3K/mTOR Signaling with Dual-Inhibitors as a New Therapeutic Strategy against Cutaneous T Cell Lymphoma
   Antonella Bresin et al, 2019, Journal of Investigative Dermatology CrossRef
4. Circular METRN RNA hsa_circ_0037251 Promotes Glioma Progression by Sponging miR-1229-3p and Regulating mTOR Expression
   Qinchen Cao et al, 2019, Sci Rep CrossRef
5. Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
   Chiara Tarantelli et al, 2020, IJMS CrossRef
6. Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma
   Maria Bhatti et al, 2018, Oncotarget CrossRef
7. Pharmacologic characterization of SHR8443, a novel dual inhibitor of phosphatidylinositol 3-kinase and mammalian target of rapamycin
   Chengying Xie et al, 2017, Oncotarget CrossRef
8. Bioinformatics analysis of microRNA expression between patients with and without latent tuberculosis infections
   Yang Lu et al, 2019, Exp Ther Med CrossRef
9. Mantle cell lymphoma: insights into therapeutic targets at the preclinical level
   Pavel Klener, 2020, Expert Opinion on Therapeutic Targets CrossRef
10. Molecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: A review
    Yuanze Wang et al, 2022, European Journal of Medicinal Chemistry CrossRef
11. Evaluation of a Dual PI3K/mTOR Inhibitor PF-04691502 against Bladder Cancer Cells.
    Xiaosong Shang et al, 2022, Evid Based Complement Alternat Med CrossRef
12. Inhibitor PF-04691502 works as a senolytic to regulate cellular senescence
    Ziqiang Fan et al, 2024, Experimental Gerontology CrossRef
13. Vertical targeting of the PI3K/AKT pathway at multiple points is synergistic and effective for non-Hodgkin lymphoma
    Kristyna Kupcova et al, 2024, Exp Hematol Oncol CrossRef